ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Xuan Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1967-3593; OpenAlex author ID A5009881958. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 17

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 3

Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. Co-author DOI 10.1038/s41392-026-02641-4 ↗
CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. Co-author DOI 10.1038/s41467-026-75132-3 ↗
The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation. Last author DOI 10.3389/fonc.2023.1151321 ↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jihui Hao · 2 shared papers, 2026 · strength 0.44
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Yu Wang · 2 shared papers, 2023–2026 · strength 0.37
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
- Paper The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation. DOI 10.3389/fonc.2023.1151321 ↗
Xiaofan Guo · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Xiuchao Wang · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Chuntao Gao · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Tiansuo Zhao · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Jun Yu · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Yongjie Xie · 1 shared paper, 2026 · strength 0.23
- Paper Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancre… DOI 10.1038/s41392-026-02641-4 ↗
Min Li · 1 shared paper, 2026 · strength 0.21
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Bo Wang · 1 shared paper, 2026 · strength 0.21
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Quan Zhou · 1 shared paper, 2026 · strength 0.21
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Xiaofan Guo · 1 shared paper, 2026 · strength 0.21
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Tianxing Zhou · 1 shared paper, 2026 · strength 0.21
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Lei Zheng · 1 shared paper, 2026 · strength 0.21
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Mien‐Chie Hung · 1 shared paper, 2026 · strength 0.21
- Paper CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer. DOI 10.1038/s41467-026-75132-3 ↗
Chao Liu · 1 shared paper, 2023 · strength 0.16
- Paper The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation. DOI 10.3389/fonc.2023.1151321 ↗
Song Gao · 1 shared paper, 2023 · strength 0.16
- Paper The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation. DOI 10.3389/fonc.2023.1151321 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.